KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amgen (AMGN) Treasury Shares (2016 - 2025)

Amgen has reported Treasury Shares over the past 16 years, most recently at $3.7 million for Q4 2025.

  • Quarterly results put Treasury Shares at $3.7 million for Q4 2025, up 164.29% from a year ago — trailing twelve months through Dec 2025 was $3.7 million (up 164.29% YoY), and the annual figure for FY2025 was $3.7 million, up 164.29%.
  • Treasury Shares for Q4 2025 was $3.7 million at Amgen, up from $1.4 million in the prior quarter.
  • Over the last five years, Treasury Shares for AMGN hit a ceiling of $26.1 million in Q4 2022 and a floor of $1.4 million in Q4 2024.
  • Median Treasury Shares over the past 4 years was $4.6 million (2021), compared with a mean of $10.4 million.
  • Peak annual rise in Treasury Shares hit 564.86% in 2022, while the deepest fall reached 67.39% in 2022.
  • Amgen's Treasury Shares stood at $21.7 million in 2021, then grew by 20.28% to $26.1 million in 2022, then tumbled by 94.64% to $1.4 million in 2024, then skyrocketed by 164.29% to $3.7 million in 2025.
  • The last three reported values for Treasury Shares were $3.7 million (Q4 2025), $1.4 million (Q4 2024), and $26.1 million (Q4 2022) per Business Quant data.